Shanghai Institute of Materia Medica, Chinese Academy of Sciences
CN | CAS  
 
  Home | Links | Site map
 
Home About Us News Organization Research Faculty Publication Education&Training Contact
  News
Location: Home > News > Events
 
 
Events
 
The President of the Portuguese Republic witnesses the Signing of SIMM-UMinhoMoU and SIMM-Techno Phage Collaboration Agreement
Update time: 2014-05-14
Close
Text Size: A A A
Print
Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM) signed today (May 14th) a Memorandum of Understanding with University of Minho (UMinho), a Portuguese public university, and a collaboration agreement with TECHNOPHAGE, a biotechnology company headquartered in Lisbon, Portugal. The unique partnerships were announced at SIMM during the state visit of His Excellency the President of the Republic of Portugal to China.

The SIMM-UMinhoMoU is to create a cooperation platform which should foster collaboration, provide opportunity for global experience, joint applications to research programs in the European Union (EU) and in China, exchange of students and staffs, protection and valorization of new technologies, and to facilitate advancement of knowledge on the basis of reciprocity, best effort, mutual benefit, and frequent interactions.

TechnoPhage is developing small domain antibodies against specific targets in several human diseases with proprietary technology. Based on this technology, a new R&D program has now been started jointly with SIMM to develop TA-141. TA-141 will be developed for the treatment of inflammatory and autoimmune diseases and is expected to have global reach. The programme will undergo discovery stages for the engineering of the new product, production and preclinical safety studies in order to generate data to support regulatory filings for clinical trials.

Professor Hualiang Jiang, Director General of SIMM said:“SIMM is to develop long-term collaboration with Portuguese institutions and companies from which we expect to deliver fruitful results in the near future”.

Professor António Cunha, Rector of UMinho said:“the excellent and complementary research performed at SIMM and UMinho as well as the objective of both institutions to increase the economic impact of their developments, open a true opportunity to develop an effective international collaboration.”

Miguel Garcia, President and CEO of TechnoPhage said: “This second programme with SIMM is a great opportunity for TechnoPhage and further shows the capabilities the company has developed in recent years in antibody biopharmaceuticals. We are extremely pleased that the SIMM has decided to enter a second programme with TechnoPhage and will commit all required resources to meet the milestones established with our partner.”


About University of Minho
The UMinho, founded in 1973 is based in two campi, in the cities of Braga and Guimarães, in the Northwest of Portugal. It is a comprehensive university with 11 Schools and more than 19,000students, having an important research activity in life and health sciences, including drug delivery, regenerative medicine, and tissue engineering.

About TechnoPhage
TechnoPhage is a biotechnology company focused on the R&D of new molecules in several therapeutic areas. The company’s laboratories are located in the facilities of the Instituto de Medicina Molecular, with whom TechnoPhage has a scientific collaboration protocol.
The company’s strategy is based on the use of its several technology platforms, in order to identify new molecules with potential for different therapeutic areas. After being identified, the molecules proceed to the development stage. At this moment, the company is conducting 11 programs within its pipeline of new therapeutic molecules, one of them being already in the last phases of preclinical tests, for the rheumatoid arthritis indication. In February 2014, TechnoPhage has also filed an Investigational New Drug application at the USA Food and Drug Administration for the clinical development of a new anti-microbial drug.

About SIMM
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences evolved from the Institute of Materia Medica of Peking Academy of Sciences founded in 1932. Its current location is within the heart of Zhang Jiang Hi-Tech Park, Pudong New District.
SIMM’s mission is to provide a comprehensive solution in drug discovery and development. By combining basic and applied research efforts and through cross-fostering between chemistry and biology, scientists at SIMM carry out studies toward the elucidation of the structural basis of bioactive substances, discovery of new targets or mechanisms of action, comprehensive pre-clinical evaluation of drug candidates, and promotion of commercialization, thereby playing an indispensable role in building China’s drug innovation capabilities. The major research directions of SIMM include drugs against diseases seriously endangering the health of Chinese people such astumor, cardiovascular disease, neurological disease, metabolic disease, autoimmune disease as well as infectious disease. Another task for SIMM is to strengthen research and development of Traditional Chinese Medicine.

The President of the Portuguese Republic and First Lady visit SIMM(Image by SIMM)

Signing of SIMM-UMinhoMoU Memorandum of Understanding(Image by SIMM)

Signing of SIMM-Techno Phage Collaboration Agreement(Image by SIMM)

The attendees of signing ceremony(Image by SIMM)

 

 
weimoban
About Us News Research Faculty Education&Trainning Organization Contact
Brief Introduction
History
Address from the Director
Directors
Administration
Research
Events
Int'l cooperation
Target
Discovery
Development
Translation
Academician
PI
Graduate Students
Post Graduate Students